Lenvatinib Mesylate Intermediate CAS 205448-65-3 Kemurnian >98,0% (HPLC) Pabrik
Pasokan Kimia Ruifu Lenvatinib Mesylate Intermediates Kanthi Kemurnian Dhuwur
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Metil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimetil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Jeneng Kimia | Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
sinonim | 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Lenvatinib Intermediate 3 |
Nomer CAS | 205448-65-3 |
Nomer CAT | RF-PI1973 |
Status Simpenan | Ing Simpenan, Kapasitas Produksi 50 MT / Taun |
Formula Molekul | C12H11NO4 |
Bobot Molekul | 233.22 |
Titik didih | 421,0 ± 45,0 ℃ |
Kapadhetan | 1,267±0,060 g/cm3 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Bubuk Putih nganti Kuning |
Kemurnian / Metode Analisis | > 98,0% (HPLC) |
Mundhut ing Pangatusan | <1.00% |
Sisa ing Ignition | <0,50% |
Total Impurities | <2.00% |
H-NMR | Conforms kanggo Struktur |
Test Standar | Standar Perusahaan |
Panggunaan | Perantara Farmasi |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) minangka perantara saka Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, sing didol nganggo jeneng merek Lenvima antara liya, minangka obat anti-kanker kanggo perawatan kanker tiroid tartamtu lan uga kanker liyane.Iki dikembangake dening Eisai Co. lan tumindak minangka inhibitor kaping kinase marang kinase VEGFR1, VEGFR2 lan VEGFR3.Lenvatinib disetujoni (wiwit 2015) kanggo perawatan kanker tiroid sing beda-beda sing kedadeyan sacara lokal utawa metastatik, progresif, lan ora nanggapi perawatan karo yodium radioaktif (radioiodine).Ing Mei 2016, US Food and Drug Administration (FDA) nyetujoni (ing kombinasi karo everolimus) kanggo perawatan karsinoma sel ginjel lanjut sawise siji terapi anti-angiogenik sadurunge.Obat kasebut uga disetujoni ing AS lan ing Uni Eropa kanggo karsinoma hepatoseluler sing ora bisa diilangi kanthi bedah ing pasien sing durung nampa terapi kanker kanthi tutuk utawa injeksi.